The Scripps Research Institute (TSRI)

Autobahn Therapeutics wanted to take advantage of the neuropsychiatric benefits observed with thyroid hormone therapy without systemic side effects, so the company used its proprietary technology for

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

It is too soon for the Pitchbook and National Venture Capital Association (NVCA) Venture Monitor report detailing fourth quarter 2022 VC investment, including a breakdown of biopharmaceutical fundra

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s